Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 6,239 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 6,239 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40. Following the completion of the transaction, the chief operating officer now owns 231,401 shares of the company's stock, valued at $10,320,484.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $296,636.65.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $0.12 during mid-day trading on Friday, hitting $45.40. 638,602 shares of the stock were exchanged, compared to its average volume of 941,083. Twist Bioscience Co. has a 12-month low of $15.85 and a 12-month high of $60.90. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The stock's fifty day simple moving average is $43.69 and its two-hundred day simple moving average is $45.64.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience during the 3rd quarter worth $43,992,000. Point72 Asset Management L.P. grew its holdings in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock worth $33,168,000 after buying an additional 613,057 shares during the last quarter. Fred Alger Management LLC grew its holdings in shares of Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock worth $32,272,000 after buying an additional 575,080 shares during the last quarter. Victory Capital Management Inc. raised its stake in Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock valued at $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in Twist Bioscience during the 2nd quarter valued at approximately $9,462,000.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a report on Monday, August 5th. Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Barclays lowered their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.